HCV care gaps in US identified by treatment cascade

  • March 11, 2014

A treatment cascade for hepatitis C patients in the United States identified gaps in care and pointed to a need for improvements in diagnosis, fibrosis staging, antiviral therapies and sustained viral response, according to data from the 2014 Conference on Retroviruses and Opportunistic Infections.

Using Medline, Embase and the Cochrane Database of Systematic Reviews (January 2003 to July 2013), researchers established a hepatitis C treatment cascade and estimated the number of chronic HCV-infected individuals in the US at each stage of the model.

Of the 9,581 studies identified, 120 were reviewed, and seven met inclusion criteria. Meta-analytic techniques were applied when multiple studies addressed key questions.

The population data for the cascade indicated 3.5 million individuals have chronic HCV infection, including:

  • 50% diagnosed and aware of their infection (95% CI, 43-57)
  • 46% with access to outpatient care (95% CI, 41-51)
  • 29% received HCV RNA confirmation tests (95% CI, 28-30)
  • 20% underwent fibrosis staging (95% CI, 19-21)
  • 17% received antiviral therapy (95% CI, 16-17)
  • 9% achieved sustained viral response (95% CI, 9-10)

“As antiviral therapy for chronic hepatitis C virus advances to become more convenient, effective, and better-tolerated, identifying gaps in HCV care will become increasingly important to clinicians, public health officials and federal agencies,” the researchers wrote.

For more information:

Yehia BR. #669. The Treatment Cascade for People With Chronic Hepatitis C Virus Infection in the United States. Presented at: 2014 CROI; March 3-6, 2014; Boston.

Disclosure: Baligh R. Yehia reports no relevant financial disclosures.